To read the full story, subscribe or sign in.

Parvus enters agreement to advance PVT-201 for primary biliary cholangitis

Dec. 1, 2021

Parvus Therapeutics has announced an agreement with National Resilience for the tech transfer, scale-up and GMP manufacturing of PVT-201, Parvus' lead Navacim drug candidate being developed to treat primary biliary cholangitis.

BioWorld Science Collaboration Gastrointestinal

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...